Top 10 Medical Stocks To Invest In 2019

Fresenius Medical Care AG & Co. KGaA (ETR:FME) received a €107.00 ($124.42) price target from equities researchers at HSBC in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the stock. HSBC’s price objective indicates a potential upside of 21.04% from the stock’s current price.

FME has been the subject of several other reports. JPMorgan Chase & Co. set a €96.10 ($111.74) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Thursday, July 26th. Barclays set a €90.00 ($104.65) target price on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Friday, May 4th. Berenberg Bank set a €100.80 ($117.21) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Tuesday, July 31st. Credit Suisse Group set a €91.00 ($105.81) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Tuesday, July 31st. Finally, Commerzbank set a €82.00 ($95.35) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Tuesday, July 31st. Nine investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of €95.23 ($110.73).

Top 10 Medical Stocks To Invest In 2019: SteadyMed Ltd.(STDY)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Steadymed Ltd (NASDAQ:STDY) CEO Jonathan Rigby sold 88,831 shares of the company’s stock in a transaction on Friday, August 17th. The stock was sold at an average price of $4.66, for a total transaction of $413,952.46. Following the completion of the sale, the chief executive officer now owns 41,605 shares of the company’s stock, valued at $193,879.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Top 10 Medical Stocks To Invest In 2019: Intercept Pharmaceuticals, Inc.(ICPT)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    It’s another disappointing day for one of America’s top biotech companies. Gilead Sciences Inc.’s (NASDAQ: GILD) selonsertib failed to improve fibrosis in the Phase 3 STELLAR-4 trial, and its shares traded lower as a result. While this is more bad news for Gilead, it may prove to be great news for Intercept Pharmaceuticals Inc. (NASDAQ: ICPT).

  • [By Max Byerly]

    JMP Securities upgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a market perform rating to an outperform rating in a research report report published on Wednesday morning, Marketbeat.com reports. JMP Securities currently has $175.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $75.00.

  • [By Sean Williams]

    As you can see, there’s a lot of excitement in the NASH space at the moment, and plenty of big drug stocks are itching to add a promising NASH drug to their product pipelines. But one name that continues to be left out in the cold is Intercept Pharmaceuticals (NASDAQ:ICPT).

Top 10 Medical Stocks To Invest In 2019: Phillips 66(PSX)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Refining giant Phillips 66 (NYSE:PSX) and Canadian energy infrastructure behemoth Enbridge (NYSE:ENB) initially pitched Gray Oak to oil shippers in early December. At the time, they envisioned a 385,000 barrel-a-day pipeline that would move crude from several connection points in West Texas to refineries and export docks along the Texas coast starting in the second half of 2019.

  • [By Reuben Gregg Brewer]

    In January, oil and natural gas refinery Valero Energy Corporation’s (NYSE:VLO) shares jumped 17%, according to data provided by S&P Global Market Intelligence. That was the biggest gain of this trio, but Marathon Petroleum Corp. (NYSE:MPC) and its 12% gain wasn’t far behind. Even Phillips 66 (NYSE:PSX) got in the act with a nearly 11% gain. All of them beat the roughly 8% rise in the S&P 500 index.

  • [By Max Byerly]

    Phillips 66 (NYSE: PSX) and Vertex Energy (NASDAQ:VTNR) are both oils/energy companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

  • [By Shane Hupp]

    HPM Partners LLC grew its position in Phillips 66 (NYSE:PSX) by 10.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,411 shares of the oil and gas company’s stock after buying an additional 1,059 shares during the period. HPM Partners LLC’s holdings in Phillips 66 were worth $1,282,000 as of its most recent SEC filing.

  • [By Logan Wallace]

    Payden & Rygel lifted its stake in shares of Phillips 66 (NYSE:PSX) by 46.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 199,700 shares of the oil and gas company’s stock after buying an additional 63,100 shares during the quarter. Phillips 66 makes up approximately 1.6% of Payden & Rygel’s portfolio, making the stock its 25th biggest position. Payden & Rygel’s holdings in Phillips 66 were worth $19,155,000 at the end of the most recent reporting period.

Top 10 Medical Stocks To Invest In 2019: Altisource Residential Corporation(RESI)

Advisors’ Opinion:

  • [By Shane Hupp]

    Front Yard Residential Corp (NYSE:RESI) was the target of some unusual options trading activity on Thursday. Traders bought 3,877 put options on the company. This is an increase of approximately 899% compared to the average volume of 388 put options.

  • [By Logan Wallace]

    Vonovia SE Depository Receipt (NYSE: RESI) and Front Yard Residential (NYSE:RESI) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

  • [By Logan Wallace]

    Front Yard Residential (NYSE:RESI) issued its quarterly earnings data on Tuesday. The real estate investment trust reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02), Morningstar.com reports. Front Yard Residential had a negative return on equity of 25.77% and a negative net margin of 196.93%.

Top 10 Medical Stocks To Invest In 2019: VOC Energy Trust(VOC)

Advisors’ Opinion:

  • [By Shane Hupp]

    Deutsche Bank AG reduced its position in VOC Energy Trust (NYSE:VOC) by 64.5% in the 4th quarter, Holdings Channel reports. The firm owned 19,000 shares of the oil and gas producer’s stock after selling 34,500 shares during the period. Deutsche Bank AG’s holdings in VOC Energy Trust were worth $112,000 as of its most recent filing with the SEC.

Top 10 Medical Stocks To Invest In 2019: Encana Corporation(ECA)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Encana (NYSE:ECA) (TSE:ECA) had its target price raised by Morgan Stanley from $16.00 to $20.00 in a research report report published on Wednesday morning. Morgan Stanley currently has a buy rating on the oil and gas company’s stock.

  • [By Stephan Byrd]

    Cenovus Energy (NYSE:CVE) and Encana (NYSE:ECA) are both large-cap oils/energy companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

  • [By Max Byerly]

    Here are some of the news stories that may have effected Accern Sentiment’s rankings:

    Get Encana alerts:

    Encana Corp (ECA) Rising Higher 7.95% Over the Past Four Weeks (fisherbusinessnews.com) Encana Corporation (ECA) Most Active Stock Price trades 19.10% off from 200- SMA (nasdaqchronicle.com) Mid-Day Movers –: Encana Corporation (NYSE:ECA), CSX Corporation (NASDAQ:CSX), MGIC Investment Corporation … (journalfinance.net) Featured Stock: Encana Corporation (ECA) (stockquote.review) Active Stock Evaluation – Encana Corporation (NYSE: ECA) (financerater.com)

    ECA has been the subject of a number of research analyst reports. Morgan Stanley raised shares of Encana from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $15.00 to $18.00 in a report on Wednesday, January 24th. Evercore ISI raised shares of Encana from an “in-line” rating to an “outperform” rating and upped their price target for the company from $10.84 to $16.00 in a report on Wednesday, March 7th. Zacks Investment Research downgraded shares of Encana from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. Scotiabank raised shares of Encana from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $13.00 to $14.00 in a report on Friday, February 16th. Finally, Goldman Sachs cut their price target on shares of Encana from $17.25 to $14.00 and set a “buy” rating for the company in a report on Friday, April 13th. Two analysts have rated the stock with a sell rating, two have given a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $15.28.

  • [By Ethan Ryder]

    Electra (CURRENCY:ECA) traded down 22.1% against the dollar during the 1 day period ending at 11:00 AM Eastern on August 14th. One Electra coin can currently be purchased for approximately $0.0004 or 0.00000007 BTC on cryptocurrency exchanges including Cryptohub, CryptoBridge, Cryptopia and Novaexchange. In the last seven days, Electra has traded 36.7% lower against the dollar. Electra has a total market capitalization of $11.78 million and approximately $119,848.00 worth of Electra was traded on exchanges in the last day.

Top 10 Medical Stocks To Invest In 2019: ProShares UltraShort Nasdaq Biotechnology(BIS)

Advisors’ Opinion:

  • [By Shane Hupp]

    Bismuth (BIS) uses the hashing algorithm. Its genesis date was May 1st, 2017. Bismuth’s total supply is 11,579,876 coins and its circulating supply is 11,011,069 coins. The Reddit community for Bismuth is /r/cryptobismuth and the currency’s Github account can be viewed here. The official message board for Bismuth is bismuth.cz/forum. Bismuth’s official Twitter account is @cryptobismuth and its Facebook page is accessible here. The official website for Bismuth is bismuth.cz.

  • [By Ethan Ryder]

    Bismuth (BIS) uses the hashing algorithm. Its launch date was May 1st, 2017. Bismuth’s total supply is 10,193,595 coins and its circulating supply is 9,644,979 coins. The Reddit community for Bismuth is /r/cryptobismuth and the currency’s Github account can be viewed here. The official website for Bismuth is bismuth.cz. Bismuth’s official Twitter account is @cryptobismuth and its Facebook page is accessible here. The official message board for Bismuth is bismuth.cz/forum.

  • [By Shane Hupp]

    News articles about ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProShares UltraShort Nasdaq Biotechnology earned a news impact score of 0.15 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.2593843139852 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

  • [By Shane Hupp]

    Bismuth (CURRENCY:BIS) traded 8.1% lower against the US dollar during the 24-hour period ending at 21:00 PM ET on June 17th. Bismuth has a total market cap of $14.34 million and $48,199.00 worth of Bismuth was traded on exchanges in the last day. One Bismuth coin can now be purchased for $1.35 or 0.00020851 BTC on major exchanges including Cryptopia and Octaex. During the last week, Bismuth has traded down 8.5% against the US dollar.

Top 10 Medical Stocks To Invest In 2019: Pluristem Therapeutics Inc.(PSTI)

Advisors’ Opinion:

  • [By Max Byerly]

    Momenta Pharmaceuticals (NASDAQ: MNTA) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Pluristem Therapeutics Inc. (NASDAQ:PSTI) has been given a consensus recommendation of “Buy” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $4.00.

Top 10 Medical Stocks To Invest In 2019: AVG Technologies N.V.(AVG)

Advisors’ Opinion:

  • [By Shane Hupp]

    FinnCap cut shares of Avingtrans (LON:AVG) to a corporate rating in a research report report published on Monday.

    Shares of LON:AVG opened at GBX 223 ($2.97) on Monday. Avingtrans has a one year low of GBX 174.11 ($2.32) and a one year high of GBX 260 ($3.46).

Top 10 Medical Stocks To Invest In 2019: PetMed Express, Inc.(PETS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Media headlines about Petmed Express (NASDAQ:PETS) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Petmed Express earned a news impact score of 0.05 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.0051994773148 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

  • [By Steve Symington]

    Nevertheless, several individual stocks failed to keep up. Read on to see why CTI BioPharma (NASDAQ:CTIC), PetMed Express (NASDAQ:PETS), and Pfizer (NYSE:PFE) each slumped today.

  • [By Jason Hall, George Budwell, and Daniel Miller]

    For instance, TerraForm Power Inc. (NASDAQ:TERP) is easy to miss because it operates in what’s still something of a niche: owning renewable energy projects and selling the electricity to utilities and industrial users. Then you have Stanley Black & Decker, Inc. (NYSE:SWK), the company behind a handful of relatively well-known tool brands but not one that’s widely known among investors. It can get even more obscure, like Petmed Express Inc. (NASDAQ:PETS), the online pet pharmacy that’s certainly not a household name for most people and certainly not investors. 

  • [By Logan Wallace]

    Petmed Express Inc (NASDAQ:PETS) has received an average rating of “Hold” from the nine research firms that are presently covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $39.00.

  • [By ]

    PetMed Express (PETS) : “No, no, no, no. When we want pet drugs, we want Idexx Laboratories (IDXX) .”

    Xerox (XRX) : “I’d sell Xerox. That’s a house of pain.”

  • [By Timothy Green, Tyler Crowe, and Sean Williams]

    Three of our Motley Fool contributors want you to know about A.O. Smith (NYSE:AOS), Kulicke & Soffa Industries (NASDAQ:KLIC), and PetMed Express (NASDAQ:PETS). Read on to find out why these unknown but amazing dividend stocks belong in your portfolio.

Leave a Reply

Your email address will not be published. Required fields are marked *